Novoste preparing IDE for low-dose radiation system used to inhibit restenosis.
This article was originally published in The Gray Sheet
Executive Summary
NOVOSTE IDE FOR ANTI-RESTENOSIS ENDOVASCULAR BETA RADIATION SYSTEM is expected to be submitted to FDA before the end of May, company President and CEO Thomas Weldon told attendees of the Alex. Brown & Sons health care seminar in Baltimore on May 16. In an effort called "Project Beta," privately held Novoste is developing a catheter system intended to prevent restenosis after balloon angioplasty or atherectomy through the delivery of endovascular low-dose beta radiation at the site of the coronary intervention immediately after the procedure.